Thymosin Alpha-1: What the Research Shows
Also known as: Tα1, Thymalfasin, Zadaxin
A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.
This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before making any health decisions. Full disclaimer
Quick Facts
Regulatory Status
Not FDA-approved in the US. Approved in over 35 countries (as Zadaxin) for hepatitis B and as an immune adjuvant. Orphan drug designation in the US for hepatitis B.
Researched Applications
Key Research (1 studies cited)
Thymalfasin: clinical pharmacology and antiviral applications
reviewTuthill CW, et al. (2010) — BioDrugs
Comprehensive review of thymosin alpha-1 clinical data spanning over 100 clinical trials in hepatitis, cancer, and immune deficiency.
Key finding: Thymosin alpha-1 showed consistent immune-enhancing effects across multiple clinical settings, particularly in hepatitis B.
PubMed: 20923259About this article: Written by the PeptideMark Research Team. Last reviewed 2026-03-11. All factual claims are cited to peer-reviewed sources. PubMed links open in a new tab for independent verification. Editorial methodology · Medical disclaimer
Compare Thymosin Alpha-1
See how Thymosin Alpha-1 compares to similar compounds.
Open comparison tool →The Peptide Brief
Weekly peptide research digest. No spam.